Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBP-398 in Chinese subjects with advanced solid tumors
NCT05621525Phase 1Terminated
- Sponsor
- LianBio
- Start
- Oct 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMS-986466 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by LianBio. Primary endpoints: Maximum Tolerated Dose at 28 days and Anti-tumor activity at 28 days. Started Oct 2022; status: terminated.
02
Drugs
BMS-986466
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05621525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621525.